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The bifunctional Bordetella adenylate cyclase toxin-hemolysin (ACT) penetrates target cell membranes, forms cation-selective channels
and subverts cellular signaling by catalyzing uncontrolled conversion of ATP to cAMP. While primarily targeting phagocytes expressing the
aMh2 integrin (CD11b/CD18), the toxin can also penetrate mammalian erythrocytes lacking the receptor and membrane endocytosis. We
sought here to analyze the membrane interactions of ACT in a liposome model. Insertion of ACT into liposome membranes required calcium
and caused leakage of entrapped fluorescent probes due to liposome disruption, as indicated by similar release kinetics for the f 398 Da
FITC probe and its f 4400 Da dextran conjugate. However, the non-acylated proACT, which does not penetrate cellular membranes,
exhibited higher capacity to bind and lyze liposomes than the mature toxin, showing that the fatty-acyl modification was not required for
penetration of ACT into the lipid bilayer. Individual deletions within the channel-forming, acylation and repeat domains of ACT abolished its
capacity to disrupt both liposomes and erythrocytes. In contrast to erythrocyte binding, however, the liposome binding was only lost upon a
simultaneous deletion of both the channel-forming and acylation domains, suggesting that the acylation domain was also involved in
liposome penetration of ACT. Moreover, substitutions of glutamates 509 and 516 by lysines, which strongly enhanced the channel-forming
and hemolytic activity of ACT, did not affect its capacity to disrupt liposomes. This shows that the mechanism of ACT action in cellular
membranes is not fully reproduced in liposome membranes.
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Bordetella pertussis, the agent of whooping cough,
secretes an adenylate cyclase toxin-hemolysin (ACT, AC-
Hly or CyaA) which paralyzes bactericidal activities of host
phagocytes and is able to penetrate and intoxicate a variety
of other cells [1,2]. ACT is a 1706-residue-long bifunctional
protein and consists of an amino-terminal adenylate cyclase
(AC) domain, comprising about 400 N-terminal residues0005-2736/$ - see front matter D 2003 Elsevier B.V. All rights reserved.
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Abbreviations: AC, adenylate cyclase; ACT, acylated adenylate cyclase
toxin; CyaC, ACT-activating protein; DMPC, dimyristoyl phosphatidylcho-
line; DPPC, dipalmitoyl phosphatidylcholine; FITC, fluorescein isothio-
cyanate; LUV, large unilamellar vesicle; proACT, non-acylated adenylate
cyclase toxin; RTX, Repeat in ToXin; SPC, soybean phosphatidylcholine
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E-mail address: sebo@biomed.cas.cz (P. Sˇebo).and of an RTX (Repeat in ToXin) cytolysin moiety of about
1306 residues [3,4]. The RTX moiety inserts into cellular
membranes and mediates translocation of the AC domain
into cytosol, where it binds calmodulin and catalyzes
conversion of ATP to cAMP, thereby subverting cellular
signaling [5,6]. In parallel, the RTX moiety can form small
cation-selective membrane channels that allow entry of
calcium ions and can cause colloid-osmotic cell lysis, such
as hemolysis of erythrocytes [5,7].
The RTX cytolysin moiety consists itself of a channel-
forming domain (residues 500 and 700), an acylated domain
(residues 800 to 1000) and of the characteristic glycine- and
aspartate-rich RTX domain, which contains the nonapeptide
repeats of a consensus sequence (L/I/F/)-X-G-G-X-G-X-D
[8]. Binding of calcium to these repeats induces conforma-
tional changes in the toxin molecule and promotes ACT
penetration into cells [9,10]. Like other RTX cytolysins, also
ACT is synthesized as a protoxin (proACT). It gains the
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tional palmitoylation of the q-amino group of the lysine 983,
which is catalyzed by a dedicated protein acyltransferase,
CyaC [11,12].
Lally et al. [13] have shown that the RTX a-hemolysin of
E. coli uses the beta 2 integrin CD11a/CD18 as receptor on
leukocytes. Recently, an aMh2 integrin (CD11b/CD18) was,
indeed, identified as ACT receptor on myeloid cells [14].
This goes well with the known cytotoxic activity of ACT
that ablates bactericidal functions and induces apoptosis of
host phagocytes [2,15,16]. It is noteworthy, however, that
ACT can also penetrate and intoxicate a variety of cells
lacking CD11b [1]. For a related RTX protein, HlyA, a
glycophorin was recently shown to serve as receptor on
erythrocytes [17]. While macropinocytosis of ACT was
recently reported to contribute to cytotoxic activity of
ACT on macrophages [18], ACT appears to be a unique
example of an enzymatically active toxin capable of direct
translocation across the cytoplasmic membrane of cells
lacking membrane trafficking mechanisms, such as mam-
malian erythrocytes [5,19,20]. Translocation across, but not
the mere insertion of ACT into membranes, appears to
require membrane potential [21]. Indirect evidence suggests
that formation of ACT channels involves oligomerization of
membrane-embedded ACT monomers [20,22–24] and the
inner diameter of the channels, both in erythrocyte and
artificial planar lipid bilayer membranes, was estimated to
be between 0.6 and 0.8 nm [7,25]. Recently, a predicted
transmembrane a-helix between residues 502 and 522 of
ACT was shown to play a critical role in both the translo-
cation of AC across membrane and modulation of the
channel-forming activity of the toxin [24]. A helix-breaking
E509P substitution within this segment selectively abol-
ished the capacity of ACT to deliver the AC domain into
erythrocytes. Moreover, while also abolishing AC domain
translocation, the charge-reversing lysine substitutions of
glutamates Glu-509 and Glu-516 within this putative a-
helix strongly enhanced the specific hemolytic activity of
ACT by upmodulating its capacity to form channels and by
importantly reducing their cation-selectivity [24]. These
recent results raised the hypothesis that ACT can insert into
membranes in two different conformational states, one being
a ‘translocation precursor’ allowing AC domain delivery
into cells and one being a ‘channel precursor’ whose
insertion into membranes accounts for potassium efflux
from cells and eventually yields formation of oligomeric
membrane channels [25].
Despite the recently achieved progress, the mechanism of
membrane penetration of ACT remains poorly understood.
Its analysis would greatly benefit from use of a chemically
defined membrane model free of unrelated proteins that
would allow a detailed analysis of lipid membrane inter-
actions, oligomer stoichiometry and topology of membrane
segments of ACT. In search for such a surrogate model, we
examined here the interactions ACT with artificial lipid
bilayers of liposomes.2. Materials and methods
2.1. Chemicals
Fluorescein isothiocyanate (FITC), FITC-dextran (Mr
approximately 4400), raffinose, soybean phosphatidylcho-
line (SPC type II), egg yolk phosphatidylcholine type XIIIE,
phosphatidylserine type III, SPC type IIIS, DMPC, DPPC,
trypsin and Trypsin inhibitor were purchased from Sigma.
DEAE sepharose, phenyl sepharose, calmodulin-agarose,
Sephadex G25 and proteinase K were from Amersham
Biosciences.
2.2. Production and purification of ACT
The acylated adenylate cyclase toxin (ACT) and the non-
acylated toxin (proACT) were produced in the presence, or
in the absence, of the activating protein acyltransferase CyaC
in E. coli strain XL1-Blue (Stratagene) transformed by the
appropriate expression plasmids pT7CACT1 or pACT7,
respectively [26,27]. The proteins were further purified by
ion-exchange chromatography on DEAE Sepharose and
Phenyl Sepharose [28] and stored frozen in 50 mM Tris–
HCl pH 8.0, 8M urea and 2 mM EDTA (column elution
buffer). Construction and purification of ACT variants
carrying the substitutions E509K, E516K and E509K +
E516K, respectively, were previously described [24]. Trun-
cated ACT variants, DCla (pCACTD828 – 887), DH
(pCACTD385–828), DHR1 (pCACTD385–1006), DHR2
(pCACTD385–1489), DR (pCACTD1009–1489), DC217
(pCACTDC217), DAC (pCACTD1–373) and Cter 700
(pACTD1–1008), respectively, were produced and purified
as previously described [10,29,30]. Protein DC843
(pACTD864–1706) was constructed by inserting a TAA
stop codon in frame at position 864 of the cyaA gene. DC699
(pCACTDC699) was constructed in the same way as the
ACT1007 described earlier [10], while the XhoI–ScaI frag-
ment was replaced in pCACT3, instead of pACT7. The
integrity of all proteins was systematically controlled by
SDS-PAGE and the degree of purification of all of them
exceeded 90% homogeneity (data not shown).
2.3. ACT binding to liposomes
Large unilamellar vesicles (LUVs) of mean size of 400
nm were prepared by extrusion of multilamellar hand-shaken
liposome vesicles in 50 mM Tris–HCl buffer, pH 8.0, with
150 mM NaCl, using the LiposoFast Basic apparatus (Aves-
tin, Canada) with a polycarbonate membrane of 400-nm pore
diameter (Avestin), as previously described [31].
Binding of ACT to liposomes could be assessed and
unambiguously quantified without the need for radiolabel-
ling of the toxin thanks to the very high specific AC enzyme
activity of 400 Amol of cAMP formed per milligram of ACT
protein per minute under the used assay conditions [32].
This allowed detection of the liposome-bound toxin by
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labeled [32P]-cAMP and tracing of the toxin down to
concentrations of 0.1 ng per milliliter and per milligram of
lipid (0.56 pM ACT). The proACT, ACT and truncated
ACT proteins were diluted from 50 to 100 times concen-
trated stocks to a final concentration of 56 nM within 1 ml
of liposome suspensions (LUV 400 nm) containing 1 mg of
lipid in 50 mM Tris–HCl pH 8.0, 150 mM NaCl and
containing either 2 mM CaCl2 or 2 mM EDTA. After 60
min of incubation at 37 jC, the liposomes were washed
twice in 50 mM Tris–HCl pH 8.0, 150 mM NaCl and once
in 0.1 M Na2CO3 pH 10.5. For each washing step, the
liposome suspensions were pelleted at 51 000 g for 30
min at 4 jC, resuspended in the indicated buffers and
transferred to fresh polypropylene centrifugation tubes in
order to avoid any carry-over of ACT bound to tube walls
instead of liposomes. Potential sedimentation and carry-over
of aggregated ACT proteins was controlled by omitting the
liposomes and it was found to be nil. For determination of
the AC activity of ACT bound per milligram of lipid, the
liposomes were solubilized prior to AC assay in 0.1% Triton
X-100, 50 mM Tris–HCl buffer, pH 8.0, 0.2 mM CaCl2.
The activities of intact ACT associated in the presence of 2
mM calcium ions with 1 mg of liposome lipid were taken as
the respective 100% binding activity values.
2.4. ACT binding to erythrocytes and hemolysis assay
The proACT, ACT and truncated ACT proteins were
diluted from 50 to 100 times concentrated stocks to a final
concentration of 56 nM within 1 ml of washed sheep
erythrocyte suspensions (5 108 cells/ml) in 20 mM Tris
pH 8.0, 150 mM NaCl (TN buffer) and 2 mM CaCl2 (TNC
buffer) or 2 mM EDTA (TNE buffer), respectively. After 30
min of incubation at 37jC, the unbound ACT was removed
by twowashes of the cells in TN buffer at 6000 g at 4 jC for
2 min, using fresh tubes at each step to avoid ACT carry over
on tube walls. Remaining ACT that was not integrated into
erythrocyte membrane was stripped off by a third wash in 0.1
M Na2CO3 (pH 10.5) and the cells were than lyzed in 50 mM
Tris–HCl buffer, pH 8.0, 0.2 mM CaCl2 containing 0.1%
Triton X-100 for determination of cell-bound AC activity.
The activities of intact ACT in the presence of 2 mM calcium
ions were taken as the respective 100% activity values.
To determine the effect of protease pretreatment of
erythrocytes on ACT binding and hemolysis of erythro-
cytes, the washed erythrocytes were incubated with 50 Ag/
ml of trypsin or 2 Ag/ml proteinase K (sublytic concen-
trations), for 60 min at 37 jC. Proteases were removed by
three washes of cells in TN buffer with 10 Ag/ml of trypsin
inhibitor (where applicable) and adjusted to 5 108 cells/ml
in TNC buffer before use for ACT binding assays.
Hemolytic activity of ACT on protease-treated and
control sheep erythrocytes was determined as described
earlier [29] by photometric determination of the amount
of hemoglobin released from 5 108 cells after 5 h ofincubation with the indicated toxin concentration in 1 ml
TNC at 37 jC.
2.5. Preparation of liposomes loaded by FITC
Multilamellar hand-shaken liposome vesicles were pre-
pared in 50 mMTris–HCl buffer, pH 8.0, with 150 mMNaCl
supplemented with 4.4 mM FITC, or FITC-dextran. Large
unilamellar/oligolamellar vesicles of mean size of 400 nm
(LUV400) were prepared as previously described [31], by
extrusion of hand-shaken liposome vesicles with the Lip-
osoFast Basic apparatus (Avestin) equipped with a polycar-
bonate membrane of 400 nm pore diameter (Avestin). The
non-encapsulated probe was removed by gel filtration on
Sephadex G25 columns (111.5 cm) operated in 50 mM
Tris–HCl buffer, pH 8.0, with 150 mM NaCl. Finally, the
liposomes were concentrated by centrifugation at 51 000 g
at 4 jC for 30 min and resuspended in 50 mM Tris–HCl pH
8.0 and used at lipid concentration of 1 mg/ml.
2.6. Determination of FITC release
Fluorescence intensity at 520 nm was measured using
continuously stirred 1 cm optical path cuvettes in a SLM
4800S fluorometer (SLM Instruments Inc., Urbana, IL) at
465 nm excitation wavelength and 37 jC. The release of the
entrapped FITC from liposomes was determined as increase
of FITC fluorescence intensity due to relief of self-quench-
ing of the probe upon dilution in the liposome bathing
buffer. The half-time of liposome lysis was defined as the
time needed to achieve the half-maximal increase in FITC
fluorescence intensity. The value for maximal (100%)
vesicle leakage was determined upon liposome solubiliza-
tion by 0.1% (v/v) Triton X-100. The resulting fluorescence
intensities were corrected for photobleaching and basal
increase of fluorescence intensity caused by spontaneous
leakage of liposomes in the absence of toxin. This was
typically between 8% and 10% per hour for LUVs and
between 1% and 2% per hour for multilamellar vesicles.
2.7. Determination of AC activity
AC activities were measured as previously described
[32]. One unit (U) of AC activity corresponds to 1 Amol
of cAMP formed per minute in the presence of 1 AM
calmodulin at 30 jC, pH 8.0.3. Results
3.1. ACT binds to a protease-resistant receptor on
erythrocytes
The aMh2 (CD11b/CD18) integrin was recently identi-
fied as ACT receptor on myeloid cells [14]. ACT was,
however, previously shown to penetrate also a number of
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erythrocytes. On these cells, the highly trypsin-sensitive
glycophorin was recently shown to serve as an alternate
receptor for the related RTX protein, HlyA [17]. We,
therefore, addressed the question whether ACT also binds
to a protease-sensitive receptor on erythrocytes.
Direct assessment of ACT binding to cells was possible
without the need for radiolabelling of the toxin, since the
high specific enzymatic activity allowed to trace the toxin
down to 0.56 pM concentrations (0.1 ng ACT per milliliter
of cell suspension). As shown in Fig. 1, when erythrocyte
surface proteins were digested at high concentrations of
trypsin (50 Ag/ml), or of proteinase K (2 Ag/ml), no decrease
of ACT binding or hemolytic activity was observed, as
compared to untreated cells. In contrast, the hemolyticFig. 1. Protease pretreatment of erythrocytes does not affect ACT binding
and hemolytic activity. Washed sheep erythrocytes (5 108/ml) in TN
buffer (10 mM Tris–HCl, 150 mM NaCl pH 8.0) were incubated with
trypsin (50 Ag/ml), or proteinase K (2 Ag/ml) at 37 jC for 60 min to digest
the erythrocyte surface proteins, whereupon cells were repeatedly washed
in the presence of protease inhibitors. (a) Binding of ACT to protease-
treated and control erythrocytes (RBC) was assessed as described in
Materials and methods. A representative figure is shown for one out of
three independent determinations performed in duplicates and differing by
less than 15%. (b) Hemolytic activity of 1 Ag/ml of ACT on 5 108 control
and protease-treated erythrocytes (RBC) was assessed as the amount of
hemoglobin (A541) released after 300 min of incubation of the toxin with
cells at 37 jC in TNC.activity of ACT was reproducibly even higher on prote-
ase-treated than on control erythrocytes. This suggested that
unlike HlyA, ACT does not bind to the trypsin-sensitive
glycophorin and that the ACT receptor on erythrocytes was
highly protease-resistant and it could be a non-proteinaceous
species, such as a lipid or glycolipid. This would go well
with previous observations that binding of ACT to eryth-
rocytes is essentially unsaturable and could not be compet-
itively inhibited by large excess of various ACT deletion
mutants, suggesting that the toxin receptor on erythrocytes
could be a rather abundant molecule [29].
3.2. ACT inserts into the lipid bilayer of LUVs made of pure
phospholipids
Gordon et al. [33] have previously shown that ACT can
bind and disrupt liposomes containing phospholipids, cho-
lesterol and sphingolipids. This also suggested that mem-
brane interactions of ACT could be analyzed in a chemically
defined lipid vesicle system in the absence of other proteins.
We therefore examined in detail the interaction of ACT with
large unilamellar liposomes prepared by 20 times repeated
extrusion of phospholipid suspensions through filters with a
cut-off limit of 400 nm (LUV 400 nm). As shown in Fig. 2a,
the amount of ACT bound to 1 mg of liposomes was
comparable to that of binding to 5 108 sheep erythrocytes,
even when liposomes were made of highly purified phos-
polipids, such as soybean or egg yolk phosphatidylcholine,
phosphatidylserine, or a DMPC/DPPC (1:1) mixture, re-
spectively. The bound toxin could not be removed by
repeated washing with buffer and subsequent stripping of
liposomes with 0.1 M sodium carbonate at pH 10.5, which
is an established procedure for removal of peripheral mem-
brane proteins [34]. This suggested that ACT was able to
insert into the lipid bilayer of the liposome membrane in the
absence of any receptor protein and membrane potential.
As further shown in Fig. 2a, the efficiency of ACT
binding was, however, greatly enhanced by lowering the
homogeneity of the lipid preparation. A several-fold higher
yield of bound toxin was observed with liposomes made of
soybean lecithin type IIS (Sigma), which consists of only
about 20% of phosphatidylcholine and the rest is a mixture of
other plant lipids. However, given the about 10 times smaller
total surface of 5 108 sheep erythrocytes, as compared to 1
mg of 400 nm large asolectin LUVs (f 5 1012 lipid
vesicles), about three times more ACT bound per surface
unit to the erythrocyte membranes than to asolectin LUVs.
Since the soybean lecithin liposomes exhibited the highest
binding of ACT, these were used for further analyzes.
3.3. Free calcium, but not fatty-acyl modification of the
toxin, is required for binding and disruption of liposomes
by ACT
Penetration of ACT across membranes of target cells
depends on the posttranslational palmitoylation of its
Fig. 2. ACT binds and disrupts large unilamellar liposomes of various lipid compositions in a calcium-dependent and fatty-acylation independent manner. (a)
Binding of ACT to LUV400. Unilamellar/oligolamellar liposomes were prepared by 20 times repeated extrusion of asolectin, or of highly purified lipid
suspensions through filters with a 400 nm cut-off pore size [31]. Ten micrograms of ACTwas incubated with liposomes of various composition in 1 ml of buffer
and toxin binding per milligram of lipid is shown. For comparison, binding of ACT per 5 108 washed sheep erythrocytes (RBC) was determined. (b) ACT
binding to asolectin LUV400 requires the presence of calcium ions. Purified non-acylated proACTand acylated mature ACTwere tested at 1 Ag/ml for binding to
soybean asolectin LUV400. Liposomes were prepared and washed in TN buffer and upon addition of either 2 mM calcium ions or 2mM EDTA, respectively,
ACT binding per milligram of lipid was assessed after repeated washing and 0.1 M carbonate stripping at pH 10.5, as described under Materials and methods. (c)
ACT disrupts LUV400 liposomes. Purified non-acylated proACTand ACTwere tested for disruption of asolectin LUVs (1 mg/ml) with entrapped FITC probe in
TNC buffer. Kinetics of FITC release induced by equal concentrations of ACTor proACT (160 nM) was followed at 37 jC in the presence of 2 mM calcium ions
or 2 mMEDTA, respectively. For the negative control (no toxin), a corresponding volume of 8 M urea in TNCwas added. ACTand proACTwere added at a time
point that corresponds to 1 min in the given recordings. Spontaneous leakage of FITC from LUVs over the 100 min of incubation was about 0.06 a.u. on a scale
from 0.0 to 1.0 a.u., the latter corresponded to total dequenching of FITC fluorescence caused by detergent lysis of LUVs with 0.1% Triton X-100. The figure
shows a representative set of lysis curves from one out of four independent measurements. (d) proACT disrupts MLVs faster than ACT. The dependencies of half-
times of FITC probe leakage from multilamellar liposomes on ACT and proACT concentrations were determined in TNC buffer with 4 mM calcium
concentration. Three independent determinations for each protein and condition were performed and representative data from one set of experiments are shown.
(e) Calcium requirements of ACT and proACT for liposome disruption are similar. FITC-loaded MLVs were incubated with 160 nM proACT and ACT in TNC
buffer. The probe leakage half-time corresponded to the time at which FITC fluorescence reached 0.5 a.u., e.g. 50% of total FITC dequenching caused by
detergent lysis of MLVs with 0.1% Triton X-100.
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mM free calcium ion concentrations [9,12]. As shown in
Fig. 2b, omission of calcium in the liposome bathing
buffer and chelation of residual traces of calcium ions by
2 mM EDTA resulted in 10-fold drop of liposome-
binding capacity of ACT. Hence, in this respect, the
binding of ACT to liposomes resembled toxin interaction
with cells. It should be noted that in this binding
experiment the toxin concentration was lowered to 1
Ag/ml (Fig. 2b), in order to control that formation of
toxin aggregates and their unspecific interaction with
liposomes did not account for the observed ACT binding
to liposomes. Moreover, the bound toxin could not be
stripped off from the liposome membranes by washing in
0.1 M sodium carbonate at pH 10.5, suggesting that both
ACT and proACT were inserted into liposome mem-
branes. Surprisingly, the non-acylated proACT exhibited
an about two times higher capacity to bind liposomes
than the acylated mature ACT, as further shown in Fig.
2b. Moreover, both proACT and ACT induced leakage of
the 398-Da FITC probe from liposomes, as shown in Fig.
2c and d. Correlating with the enhanced binding, also the
kinetics of liposome disruption induced by proACT was
importantly faster than that of ACT-mediated lysis. At
equal protein concentrations, the proACT induced lipo-
some lysis with two to four times shorter half-times than
mature ACT (Fig. 2d). The liposome-disrupting activity
of both proteins exhibited, however, a similar calcium
dependency, as further shown in Fig. 2e. Altogether,
these results show that the fatty-acyl modification of
ACT was by itself not required for insertion of ACT
into the lipid bilayer of liposome membrane and may
play another role in toxin activity.Fig. 3. Kinetics of toxin-mediated release of entrapped FITC and FITC-dextran
kinetics of release of FITC (398 Da) and/or FITC-dextran (f 4400 Da) from soy
FITC and FITC-dextran-probe release from LUVs was induced by 160 nM ACT o
due to dilution of the released probe in the bathing buffer and the resulting relief
fluorescence upon detergent lysis of LUVs with 0.1% Triton X-100.3.4. Membrane activity of ACT leads to formation of large
lesions in liposome membranes
Earlier osmotic protection experiments on erythrocytes
and single-channel measurements on planar lipid bilayers
with applied voltage showed that ACT forms small
cation-selective membrane channels with an inner diam-
eter between 0.6 and 0.8 nm. The ACT channels appear
too small already for diffusion of monosaccharides of
molecular mass above 100 Da [7,25] and would not
allow permeation of the 398 Da FITC probe. Indeed,
as shown in Fig. 3, a quite similar kinetics was observed
for ACT-mediated release of entrapped FITC and of the
10 times larger FITC-dextran conjugate probe (Mr ap-
proximately 4400) from liposomes. This strongly suggests
that the membrane activity of ACT (and proACT)
resulted in formation of large membrane-disrupting
lesions allowing release of the fluorescent probes. In this
respect, the activity of ACT on liposomes mimicked its
lytic activity on erythrocytes, where hemoglobin is re-
leased upon erythrocyte disruption by colloid-osmotic
lysis resulting from the membrane-permeabilizing activity
of ACT channels.
3.5. Structure–function relationships determining ACT
penetration of cellular membranes are partially reproduced
in the liposome model
It was important to analyze how well are the struc-
ture–function relationships underlying toxin activities in
cellular membranes reproduced in the surrogate membrane
model. Therefore, interaction with liposomes was exam-
ined for a set of ACT variants with deletions of individual
sica Acta 1660 (2004) 144–154 149from large unilamellar liposomes are similar. ACT- and proACT-induced
bean lecithin LUVs was compared in the presence of 4 mM calcium ions.
r proACT and was measured as increase of fluorescence intensity at 520 nm
of probe self-quenching. 1.0 a.u. corresponds to full dequenching of FITC
Fig. 4. Differences in structural requirements for ACT binding and lysis of erythrocytes and large unilamellar liposomes. (a) Schematic depiction of the various
truncated ACT variants used in this study. Deleted portions are indicated by the open bars. In the names of the plasmids the symbol 4 is followed by the
numbers of the first and last codons of the deleted parts of the ACT reading frame. In the names of the respective proteins, the numbers that follow the symbol
DC represent the number of missing C-terminal residues. (b) Deletions of individual ACT domains differently affect ACT binding to liposomes and
erythrocytes, while (c) ablating both liposome disrupting and hemolytic activities of ACT. The binding capacity and lytic activities of various truncated ACT
variants were determined at 56 nM concentrations of the respective protein incubated with either 1 mg of asolectin liposomes or with 5 108 washed sheep
erythrocytes (RBC) in 1 ml of TNC at 37 jC. The activities of 56 nM intact ACT (ACT-wt) in TNC at 2 mM calcium concentration were taken as the respective
100% activity values. Prior to testing the membrane activities, concentrations of all the ACT-derived proteins were equalized on a molar basis, by using the
known predicted molecular masses of the various truncated proteins for calculations. The 100% ACT-wt activity corresponded on average to 170 ng of toxin
bound per milligram of lipid of LUVs resupended in 1 ml of buffer, or to 56 ng of toxin bound per 5 108 erythrocytes, respectively. These levels of ACT
binding caused half-maximal toxin-mediated lysis of RBC in 5 h (hemoglobin release from 5 108 erythrocytes yielding an A541 of 1.5) and about 30% lysis of
LUV (0.3 fluorescence a.u.) in 1 h, respectively. The given activities represent the average value from three experiments performed in duplicates (n= 6).
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were previously shown to importantly affect formation of
ACT channels. As shown in Fig. 4, ACT constructs with
individual deletions of the repeat domain, the acylated
domain and/or of the channel-forming domain, respective-
ly, were all inactive in respect to binding and lysis of
sheep erythrocytes. However, deletion of none of these
individual domains caused loss of liposome insertion by
itself and all such constructs exhibited over 50% capacity
to insert into liposomes and could not be washed out from
the membranes by stripping with sodium carbonate. Only
upon a combined deletion encompassing both the channel-
forming and the acylated domains (residues 385 to 1008),
the DHR1 protein was unable to penetrate liposomes. This
suggests that in parallel to the hydrophobic channel
domain that could be expected to insert into the lipid
bilayer, also the acylated domain could be inserting into
liposome membrane, and membrane insertion of each one
of these domains was sufficient for tight association of theFig. 5. Point substitutions enhancing the channel-forming and hemolytic activities
variants carrying the substitutions of glutamates E509K, E516K and E509K+E
previously [24]. ACT binding to liposomes and erythrocytes (a) and lytic activity
legend to Fig. 4. The relative hemolytic activity of ACT mutants (b) was scored alr
kinetics induced by the mutant ACT. Average values of data obtained in three inprotein with liposomes. The structural constraints on
insertion of ACT into liposome membranes hence appear
to be much less stringent than for insertion into erythro-
cyte membrane.
However, already the deletion of residues 828 to 887
(DCla), as well as all other examined deletions in the
hemolysin moiety of ACT, ablated the capacity of the
toxin to disrupt liposomes (Fig. 4c). This shows that
liposome disruption by ACT was not due to a nonspecific
‘detergent-like’ activity of ACT, or to some artifactual
interaction of toxin aggregates with liposomes. It is very
unlikely that such unspecific membrane activity would be
lost upon deletion of the various and often rather small
portions of the toxin molecule. On the contrary, the
specific liposome-disrupting activity depended on the
structural integrity of the entire hemolysin portion of
ACT. This corresponded well with the structural con-
straints on hemolytic activity of ACT on eryhrocytes
[29].of ACT do not alter its capacity to bind and disrupt liposomes. The ACT
516K at positions 509 and 516, respectively, were prepared as described
on liposomes (b) were compared and assessed as described in detail in the
eady after 3 h of incubation with the toxins because of the much faster lysis
dependent determinations performed in duplicates are given (n= 6).
iophysica Acta 1660 (2004) 144–1543.6. Point substitutions enhancing channel-forming and
hemolytic activity of ACT do not affect its binding and lytic
activities on liposomes
To further investigate how truly does the disruption of
liposomes by ACT reproduce the mechanism underlying the
process of erythrocyte lysis, we examined the liposome
binding and lytic activities of the ACT variants carrying
single and double lysine substitutions of the glutamate
residues 509 and 516, respectively. When combined, these
substitutions were previously shown to enhance the specific
hemolytic activity of ACT by almost an order of magnitude
and to cause a strong decrease of the cation selectivity of
ACT channels in parallel to the strong increase of the
specific frequency of ACT channel formation in artificial
planar lipid bilayers under applied voltage [24]. However,
neither individually, nor in combination, did these glutamate
substitutions exhibit any effect on binding and specific
liposome disrupting activity of ACT (Fig. 5). These results
shows that the mechanism of action and/or topology of ACT
in liposomal and cellular membranes may differ.
J. Masˇı´n et al. / Biochimica et B1524. Discussion
Earlier studies showed that analysis of membrane activ-
ities of ACT could be performed in chemically defined lipid
membranes, since ACT was able to form distinct small
cation-selective and voltage-dependent channels in planar
lipid bilayers made of soybean asolectine, or pure lipids [7].
Properties of these channels, such as their inner diameter,
were similar to the estimated properties of channels formed
in the plasma membrane of sheep erythrocytes [25]. More-
over, there was an excellent correlation between the ob-
served specific channel-forming activities of the various
ACT forms in the planar lipid bilayer membranes and their
hemolytic activities on sheep erythrocytes, when activities
of the natural ACT isolated from Bordetella, that of recom-
binant ACT from E. coli, or those of various mutant ACT
forms were compared [7,24]. The minute surface of planar
lipid bilayer membranes and the low amounts of mem-
brane–incorporated ACT in this model make it, however,
very limiting for biochemical studies on ACT membrane
topology.
This motivated us to examine the membrane interaction
of ACT in detail using a liposome model. The capacity of
ACT to disrupt liposomes was previously demonstrated [33]
and liposome systems previously served fairly well for
studies on a number of other toxins [35–37]. However, as
shown here for ACT, the RTX toxins may represent a
particular class of pore-forming toxins for which interac-
tions with cellular membrane are not reproduced in lip-
osomes truly enough. It was previously shown for the
related RTX protein HlyA that the posttranslational acyla-
tion and presence of free calcium ions, which are both
essential for the biological activity of HlyA on cells, werenot necessary for liposome binding of HlyA [38–40]. In this
respect, the calcium-dependence of ACT binding to lip-
osomes reflects somewhat better the cellular interactions of
the toxin. We further show here that like for insertion and
translocation of ACT into erythrocyte membranes [29], the
liposome-disrupting capacity of ACT required the structural
integrity of the toxin. However, the same deletions that
strongly affected binding of the toxin to erythrocytes failed
to ablate binding of truncated ACT variants to liposomes.
Moreover, the activity of ACT on asolectin liposomes was
not at all affected by the lysine substitutions of glutamates
509 and 516, which strongly enhance the hemolytic activity
and the channel-forming capacity of ACT in planar asolectin
bilayers with membrane potential [24]. This points towards
possible mechanistic or structural differences in toxin activ-
ities on cellular and planar membranes, as compared to
liposomes.
The conserved requirement of structural integrity of ACT
for its capacity to cause liposome and erythrocyte disruption
suggests that at least the initial interaction of ACT with
liposomal membranes may involve similar structures as the
toxin interaction with planar bilayers and cellular mem-
branes. In this respect, the results point to a central role of
the segment deleted in the protein DCla and comprising
residues 828 to 888, which appear important for the inter-
action of ACT with both cellular and liposome membranes.
Indeed, it was previously shown that a rather conservative
substitution of the lysine 860 residue (K860) within this
segment by an arginine residue importantly reduced the
capacity of ACT to penetrate erythrocyte membranes, inde-
pendently of the acylation status of K860 [11,44]. However,
the nil effect of the substitution of glutamates 509 and 516
on liposome binding and disrupting activity of ACT sug-
gests that ACT may insert and act differently in liposome
and planar bilayer membranes. Disruption of liposomes by
ACT does, moreover, not appear to be a result of osmotic
lysis, since it could not be inhibited by externally added
raffinose (data not shown). It is conceivable that the toxin
may be inserting inappropriately into liposomal membrane
and instead of forming true cation-selective transmembrane
channels, insertion of ACT may destabilize the membrane
and result in formation of large lesions causing liposome
disruption and release of the entrapped fluorescent probe. A
similar mechanism was, indeed, recently suggested for
liposome disruption caused by HlyA [43]. This may repre-
sent a major hurdle for accurate reproduction of ACT
interactions with biological membranes in liposomes.
Surprisingly, while acylation was strictly required for
ACT channel activity in planar lipid bilayers [7,20], the
acylation was not required here for binding and disruption
of liposomes by the protoxin. Furthermore, the non-acylated
proACT exhibited even higher specific liposome binding
and lytic activity than mature ACT. This shows that the
fatty-acylation of ACT is not essential for the mere interac-
tion of the toxin with the naked lipid membrane per se. The
results, indeed, suggest that acylation of ACT may rather be
J. Masˇı´n et al. / Biochimica et Biophysica Acta 1660 (2004) 144–154 153required for interaction of ACT with other cellular compo-
nents than the cellular lipid bilayer itself. Secondly, it is
possible, that the conformations of the acylated ACT and
non-acylated proACT proteins may differ. The non-acylated
proACT may adopt a conformation allowing it to insert
more readily into the naked liposome membrane, while the
acylated ACT would adopt a conformation required for a
productive interaction with the glycocalyx or protein com-
ponents shielding the cellular membrane. Other results
suggest that acylation plays a functional role in toxin
activity, such as modulating the propensity of ACT to form
membrane oligomers. This hypothesis goes well with the
observations that modification of ACT by fatty acyl chains
of differing properties did not affect the overall capacity of
ACT to penetrate cellular membranes and it affected selec-
tively only the specific capacity of ACT to form ionic
channels and lyze erythrocytes [7,11,41,42].Acknowledgements
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